Funding Opportunities

• NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Independent Clinical Trial Not Allowed)
  (PAR-21-152)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first standard application due date for this FOA is June 12, 2021.
• NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01 Clinical Trial Required)
  (PAR-21-153)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates. The first standard application due date for this FOA is June 12, 2021.
• NINDS Program Project Grant (P01 Clinical Trial Optional)
  (PAR-21-181)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Multiple dates, see announcement.
• Research Experiences to Enhance Clinician-Scientists' Participation in NIDCDs Research (R25 Clinical Trial Not Allowed)
  (PAR-21-188)
  National Institute on Deafness and Other Communication Disorders
  Application Receipt Date(s): May 28, 2021; September 24, 2021; January 27, 2022; May 27, 2022; September 21, 2022; January 27, 2023; May 26, 2023; September 26, 2023; January 29, 2024; September 30, 2024 apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
• National Institute of General Medical Sciences (NIGMS) Bridges to the Doctorate (T32)
  (PAR-21-198)
  National Institute of General Medical Sciences
  Application Receipt Date(s): September 28, 2021; September 27, 2022; September 27, 2023 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
• Limited Competition: Clinical and Translational Science Awards (CTSA) Consortium-Wide Centers: Resources for Rapid Demonstration and Dissemination (U24 Clinical Trials Not Allowed)
  (PAR-21-203)
  National Center for Advancing Translational Sciences
  National Center for Advancing Translational Sciences
  Application Receipt Date(s): Multiple dates, see announcement.
• Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimers Disease and Related Dementias (AD/ADRD) (R01 Clinical Trial Optional)
  (PAR-21-207)
  National Institute on Aging
  Application Receipt Date(s): Multiple dates, see announcement.
• Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed)
  (PAR-21-213)
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  National Eye Institute
  National Institute of Mental Health
  National Institute of Nursing Research
  Office of Research on Women's Health
  Office of Behavioral and Social Sciences Research
  National Institute on Minority Health and Health Disparities
  Application Receipt Date(s): Multiple dates, see announcement.
• Specialized Alcohol Research Centers (P50 Clinical Trial Optional)
  (RFA-AA-21-005)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): See announcement.
• Comprehensive Alcohol Research Centers (P60 Clinical trial Optional)
  (RFA-AA-21-006)
  National Institute on Alcohol Abuse and Alcoholism
  Application Receipt Date(s): See announcement.
• Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium Coordinating Center (U24 Clinical Trial Not Allowed)
  (RFA-AG-21-035)
  National Institute on Aging
  Office of Research on Women's Health
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): Multiple dates, see announcement.
• Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimers Disease and Related Dementias (AD/ADRD) (R61/R33 Clinical Trial Required)
  (RFA-AG-22-016)
  National Institute on Aging
  Application Receipt Date(s): September 15, 2021
• Understanding HIV Reservoir Dynamics (P01, Clinical Trial Not Allowed)
  (RFA-AI-21-013)
  National Institute of Allergy and Infectious Diseases
  National Institute of Mental Health
  Application Receipt Date(s): Not Applicable
• Limited Interaction Targeted Epidemiology (LITE-2): To Advance HIV Prevention (UG3/UH3 Clinical Trial Optional)
  (RFA-AI-21-018)
  National Institute of Allergy and Infectious Diseases
  National Institute on Drug Abuse
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Mental Health
  Application Receipt Date(s): See announcement.
• Proteome Characterization Centers (PCCs) for Clinical Proteomic Tumor Analysis Consortium (U24 Clinical Trial Not Allowed)
  (RFA-CA-21-023)
  National Cancer Institute
  Application Receipt Date(s): See announcement.
• Proteogenomic Data Analysis Centers (PGDACs) for Clinical Proteomic Tumor Analysis Consortium (U24 Clinical Trial Not Allowed)
  (RFA-CA-21-024)
  National Cancer Institute
  Application Receipt Date(s): See announcement.
• Proteogenomic Translational Research Centers (PTRCs) for Clinical Proteomic Tumor Analysis Consortium (U01 Clinical Trial Not Allowed)
  (RFA-CA-21-025)
  National Cancer Institute
  Application Receipt Date(s): See announcement.
• Centers on Telehealth Research for Cancer Related Care (P50 Clinical Trial Required)
  (RFA-CA-21-029)
  National Cancer Institute
  Application Receipt Date(s): July 20, 2021
• Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R43/R44 - Clinical Trial Not Allowed)
  (RFA-DA-22-019)
  National Institute on Drug Abuse
  Application Receipt Date(s): August 10, 2021 No late applications will be accepted for this Funding Opportunity Announcement.
• Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development (R41/R42 - Clinical Trial Not Allowed)
  (RFA-DA-22-021)
  National Institute on Drug Abuse
  Application Receipt Date(s): August 10, 2021 No late applications will be accepted for this Funding Opportunity Announcement.
• Development of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (T1D) (R01 Clinical Trial Optional)
  (RFA-DK-21-006)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): October 20, 2021
• Limited Competition: Revision to the Longitudinal Monitoring of Pancreas Architecture in the Type 1 Diabetes in Acute Pancreatitis Consortium - Data Coordinating Center (T1DAPC-DCC) (U01 Clinical Trial Optional)
  (RFA-DK-21-501)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): See announcement.
• Collaboration in Regulatory Systems Strengthening and Standardization Activities to Increase Global Access to Safe and Effective Biological Products (U01) Clinical Trials Not Allowed
  (RFA-FD-21-031)
  Food and Drug Administration
  Application Receipt Date(s): July 13, 2021
• Community Engaged Research on Pregnancy Related and Associated Infections and Sepsis Morbidity and Mortality (UG3/UH3 Clinical Trial Optional)
  (RFA-HD-21-033)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): See announcement.
• BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access and Manipulation to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed)
  (RFA-MH-21-180)
  National Institute of Mental Health
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Aging
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Eye Institute
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Institute of Biomedical Imaging and Bioengineering
  Application Receipt Date(s): Multiple dates, see announcement.
• BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R01 Clinical Trial Not Allowed)
  (RFA-NS-21-013)
  National Institute of Neurological Disorders and Stroke
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Aging
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Eye Institute
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Institute of Biomedical Imaging and Bioengineering
  Office of Research on Women's Health
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): Multiple dates, see announcement.
• BRAIN Initiative: Targeted BRAIN Circuits Planning Projects TargetedBCPP (R34 Clinical Trials Not Allowed)
  (RFA-NS-21-014)
  National Institute of Neurological Disorders and Stroke
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Eye Institute
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Institute of Biomedical Imaging and Bioengineering
  Office of Research on Women's Health
  Office of Behavioral and Social Sciences Research
  Application Receipt Date(s): Multiple dates, see announcement.
• NIH Directors Pioneer Award Program (DP1 Clinical Trial Optional)
  (RFA-RM-21-015)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): September 10, 2021
• Cutting Edge Informatics Tools for Illuminating the Druggable Genome (U01 Clinical Trial Not Allowed)
  (RFA-RM-21-020)
  Office of Strategic Coordination (Common Fund)
  Application Receipt Date(s): See announcement.